Cooper Companies (NASDAQ:COO) Director Buys $165,000.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Erik Kurzius bought 2,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were acquired at an average cost of $82.50 per share, with a total value of $165,000.00. Following the acquisition, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Monday, September 29th, Lawrence Erik Kurzius purchased 2,000 shares of Cooper Companies stock. The stock was acquired at an average cost of $68.39 per share, for a total transaction of $136,780.00.

Cooper Companies Price Performance

NASDAQ COO traded up $1.44 during trading hours on Wednesday, hitting $82.48. 3,618,606 shares of the company’s stock traded hands, compared to its average volume of 2,470,440. The company has a market capitalization of $16.16 billion, a PE ratio of 43.87, a PEG ratio of 2.33 and a beta of 1.05. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $100.24. The firm’s 50-day moving average is $73.91 and its 200-day moving average is $71.74.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the company posted $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts forecast that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies announced that its Board of Directors has initiated a stock buyback plan on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Institutional Trading of Cooper Companies

Several institutional investors and hedge funds have recently bought and sold shares of COO. Alecta Tjanstepension Omsesidigt increased its position in shares of Cooper Companies by 15.8% during the third quarter. Alecta Tjanstepension Omsesidigt now owns 1,563,000 shares of the medical device company’s stock valued at $107,112,000 after acquiring an additional 213,500 shares during the last quarter. Allworth Financial LP boosted its position in shares of Cooper Companies by 23.9% during the 3rd quarter. Allworth Financial LP now owns 1,188 shares of the medical device company’s stock worth $81,000 after purchasing an additional 229 shares during the period. IFP Advisors Inc increased its holdings in Cooper Companies by 2,647.8% in the 3rd quarter. IFP Advisors Inc now owns 632 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 609 shares during the last quarter. Swiss Life Asset Management Ltd increased its holdings in Cooper Companies by 63.9% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 49,409 shares of the medical device company’s stock valued at $3,387,000 after purchasing an additional 19,264 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in Cooper Companies in the third quarter valued at approximately $1,887,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on COO. JPMorgan Chase & Co. raised their target price on Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, December 5th. The Goldman Sachs Group reissued a “sell” rating and issued a $71.00 price objective (up previously from $64.00) on shares of Cooper Companies in a report on Monday, December 8th. Robert W. Baird raised their price objective on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Stifel Nicolaus set a $95.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Morgan Stanley increased their price target on shares of Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.15.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.